Glenmarks Ryaltris nasal spray approved in EU for treatment of allergic rhinitis

Pharma-major, Glenmark Pharmaceuticals Limited announced that it is concluding the final, national phase of its marketing approval application process to enable the launch of Ryaltris nasal spray in 17 countries in the European Union.  

The launch marks the company’s first innovative product approval in the European Union (EU). Glenmark will market Ryaltris on its own in select markets and as a part of an exclusive licensing agreement signed with Glenmark in 2020. Meanwhile, Menarini Group will lead the commercialisation efforts in some countries such as France, Italy, Spain, and the Balkan region.  

Developed by Glenmark, Ryaltris is a novel fixed-dose combination nasal spray of anti-histamine and a steroid used in the treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age. It relieves symptoms of allergic rhinitis, including stuffy nose, runny nose, nasal itching, sneezing, as well as itchy, red, and watery eyes.  

Speaking on the launch, Achin Gupta, Executive Vice President, Business Head EMEA-L (Europe, Middle East, Africa, Latam) at Glenmark Pharmaceuticals stated that upwards of 25 per cent of the population in Europe suffers from the debilitating symptoms of allergic rhinitis; so, the company hopes that Ryaltris will bring some of these real benefits.   

At 3.33 pm on Monday, the shares of Glenmark Pharmaceuticals were trading at Rs 552.00, down by 1.26 per cent or Rs 7.05 per share, against a 1.06 per cent gain in the benchmark index. The 52-week high of the company is recorded at Rs 589 while its 52-week low is Rs 322.90 on BSE.